Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of EGCG palmitate to drugs for treating or preventing hepatitis C virus infection

A technology of hepatitis C virus and palmitate, which is applied in the direction of antiviral agents, can solve problems such as the treatment effect of hepatitis C virus that is not mentioned, and achieve the effects of reducing replication efficiency, stabilizing results, and improving preventive effects

Inactive Publication Date: 2014-11-12
武汉胜达康生物科技有限公司
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No mention of its therapeutic effect on hepatitis C virus infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of EGCG palmitate to drugs for treating or preventing hepatitis C virus infection
  • Application of EGCG palmitate to drugs for treating or preventing hepatitis C virus infection
  • Application of EGCG palmitate to drugs for treating or preventing hepatitis C virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Embodiment 1: the toxicity test of EGCG palmitate to host cell,

[0039] When the HuH7 cells cultured for 24-48 hours are almost covered with a monolayer, discard the cell culture medium, add trypsin to digest, transfer to a 96-well sterile cell culture plate, 100 μl per well (1*10 5cell / ml, the same below). Place it in a cell culture incubator for 18-24 hours to make the cells grow into a single layer for later use. Dilute the EGCG palmitate stock solution (DMSO configuration, mass volume ratio 50mg / mL) with the cell maintenance solution to make five concentration gradients, and then add different concentrations of drugs to the cell culture in which the cell culture solution was discarded In the wells, 100 μl per well, repeat 3 wells for each concentration, and set up cell control wells (no drug addition, 99uL culture solution + 1uL DMSO), blank wells (no cells, only add cell culture solution), set at 37 ° C, cell culture In the box, after culturing for 48 hours, add...

Embodiment 2

[0044] Embodiment 2: HCV is to the mensuration of cell half infection dose (TCID50)

[0045] Transfer the HuH7 cells cultured into a monolayer to a 96-well cell culture plate, and culture them in a cell culture incubator for 18-24 hours. The virus stock solution was serially diluted 10 times with cell maintenance solution (10 -1 -10 -8 ). Discard the culture medium in each well of HuH7 cultured into a single layer, wash each well with PBS 3 times, add 100 μl of virus dilution solution of different concentrations to each well, absorb at 37°C for 1.5 h, discard the virus dilution solution, and add to each well 100 μl of maintenance solution, each concentration was repeated 3 times, and normal cell control wells (without adding virus) were set. The cytopathic changes (CPE) in each well were observed daily for 3 consecutive days, and the CPE conditions were recorded. Then calculate the cell half infection amount of the virus by the Reed-Muench method, and the converted virus t...

Embodiment 3

[0047] Antiviral Effect of EGCG Palmitate on HCV

[0048] 1) Preventive effect of EGCG palmitate on HCV virus

[0049] When the HuH7 cells cultivated for 24-48 hours are almost covered with a single layer, discard the cell culture medium, add trypsin to digest, and transfer to a 12-well sterile cell culture plate, 1 mL per well. Place it in a cell culture incubator for 18-24 hours to make the cells grow into a single layer for later use. Dilute the EGCG palmitate stock solution with the cell maintenance solution into five concentration gradients required for the experiment. After dilution, add different concentrations of the drug into the cell culture wells where the culture solution was discarded, 1mL per well, each concentration Repeat 3 wells, and set up antiviral positive control cell wells (add virus, add IFN-α1 to 1000U / mL, add culture medium), virus control wells (do not add drugs, add virus, add cell maintenance solution) and cell control wells (No virus, no medicine...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of the new application of drugs and particularly discloses the application of EGCG palmitate to the drugs for treating or preventing hepatitis C virus infection. The application verifies that the EGCG palmitate has the good antiviral effect in the test of in-vitro hepatitis C virus infection cells, and can prevent and treat the hepatitis C virus infection, the effect of the EGCG palmitate is equal to the that of positive control drugs IFN-alpha1, and the EGCG palmitate has the prospect for developing the drugs resisting hepatitis C viruses.

Description

technical field [0001] The invention relates to the technical field of new medical applications, and more specifically relates to the application of EGCG (epigallocatechin gallate) palmitate in the preparation of medicines for treating or preventing hepatitis C virus infection. Background technique [0002] The hepatitis C virus was first discovered in 1974 and named in 1989. Hepatitis C is mainly a viral infectious disease formed by hepatitis C virus transmitted through blood. According to the statistics of the World Health Organization, there are 1.3-1.7 million patients worldwide. Of every 100 infected persons, 75-85% of patients will develop chronic infection, 60-70% will develop into chronic disease, and 5-20% of patients will cause liver cirrhosis or even hepatocellular carcinoma (HCC) and death. It can be seen that hepatitis C is extremely harmful to the health and life of patients, and has become a serious social and public health problem. [0003] Hepatitis C viru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/353A61P31/14
Inventor 吴建国徐德邬开朗刘倩瑛刘映乐潭秋萍刘芳
Owner 武汉胜达康生物科技有限公司